Research sites in Florida, Illinois, Kansas, Texas, and New York are now recruiting participants for The Global Alzheimer’s Platform Foundation® (GAP)’s Bio-Hermes Study – a breakthrough Alzheimer’s clinical trial searching for cost-effective methods to assess the signs of the disease. It is the first-ever Alzheimer’s study to prioritize diversity in its recruitment goals.
Black Americans 65 years and older are three times more likely to develop Alzheimer’s disease than white people. This disparity is likely even greater considering that African Americans are less likely to be diagnosed with the condition and are often misdiagnosed. When they do receive an Alzheimer’s diagnosis, it’s often later in life when treatment options are more limited.
For Black physicians across the country, this worsening public health crisis is particularly concerning. The increased prevalence of Alzheimer’s disease in the Black community – two-to-three times the prevalence in white communities – is made worse by the reality that Alzheimer’s risk coincides with other conditions that disproportionately affect Black Americans (such as Diabetes, Heart Disease, and Obesity).
